Global Neuraminidase Inhibitors Drug Industry Research Report 2021 Segmented by Major Market Players, Types, Applications and Countries Forecast to 2027
Date: Apr-2021 | Id: MACRC-51605 | Geographical Scope: Global | Publisher: HNY Research
The global Neuraminidase Inhibitors Drug market is expected to reach US$ XX Million by 2027, with a CAGR of XX% from 2020 to 2027, based on HNY Research newly published report. The prime objective of this report is to provide the insights on the post COVID-19 impact which will help market players in this field evaluate their business approaches. Also, this report covers market segmentation by major market verdors, types, applications/end users and geography(North America, East Asia, Europe, South Asia, Southeast Asia, Middle East, Africa, Oceania, South America). By Market Verdors: Roche Daiichi Sankyo GSK Gilead Sciences By Types: Oseltamivir Zanamivir Peramivir Laninamivir By Applications: Hospital Pharmacy Retail Pharmacy Online Pharmacy Others Key Indicators Analysed Market Players & Competitor Analysis: The report covers the key players of the industry including Company Profile, Product Specifications, Production Capacity/Sales, Revenue, Price and Gross Margin 2016-2027 & Sales with a thorough analysis of the market’s competitive landscape and detailed information on vendors and comprehensive details of factors that will challenge the growth of major market vendors. Global and Regional Market Analysis: The report includes Global & Regional market status and outlook 2016-2027. Further the report provides break down details about each region & countries covered in the report. Identifying its sales, sales volume & revenue forecast. With detailed analysis by types and applications. Market Trends: Market key trends which include Increased Competition and Continuous Innovations. Opportunities and <b>Drivers:</b> Identifying the Growing Demands and New Technology Porters Five Force Analysis: The report provides with the state of competition in industry depending on five basic forces: threat of new entrants, bargaining power of suppliers, bargaining power of buyers, threat of substitute products or services, and existing industry rivalry. Key Reasons to Purchase To gain insightful analyses of the market and have comprehensive understanding of the global market and its commercial landscape. Assess the production processes, major issues, and solutions to mitigate the development risk. To understand the most affecting driving and restraining forces in the market and its impact in the global market. Learn about the market strategies that are being adopted by leading respective organizations. To understand the future outlook and prospects for the market. Besides the standard structure reports, we also provide custom research according to specific requirements.
1 Report Overview 1.1 Study Scope and Definition 1.2 Research Methodology 1.2.1 Methodology/Research Approach 1.2.2 Data Source 1.3 Key Market Segments 1.4 Players Covered: Ranking by Neuraminidase Inhibitors Drug Revenue 1.5 Market Analysis by Type 1.5.1 Global Neuraminidase Inhibitors Drug Market Size Growth Rate by Type: 2021 VS 2027 1.5.2 Oseltamivir 1.5.3 Zanamivir 1.5.4 Peramivir 1.5.5 Laninamivir 1.6 Market by Application 1.6.1 Global Neuraminidase Inhibitors Drug Market Share by Application: 2022-2027 1.6.2 Hospital Pharmacy 1.6.3 Retail Pharmacy 1.6.4 Online Pharmacy 1.6.5 Others 1.7 Coronavirus Disease 2019 (Covid-19) Impact Will Have a Severe Impact on Global Growth 1.7.1 Covid-19 Impact: Global GDP Growth, 2019, 2021 and 2022 Projections 1.7.2 Covid-19 Impact: Commodity Prices Indices 1.7.3 Covid-19 Impact: Global Major Government Policy 1.8 Study Objectives 1.9 Years Considered 2 Global Neuraminidase Inhibitors Drug Market Trends and Growth Strategy 2.1 Market Top Trends 2.2 Market Drivers 2.3 Market Challenges 2.4 Porter’s Five Forces Analysis 2.5 Market Growth Strategy 2.6 SWOT Analysis 3 Global Neuraminidase Inhibitors Drug Market Players Profiles 3.1 Roche 3.1.1 Roche Company Profile 3.1.2 Roche Neuraminidase Inhibitors Drug Product Specification 3.1.3 Roche Neuraminidase Inhibitors Drug Production Capacity, Revenue, Price and Gross Margin (2016-2021) 3.2 Daiichi Sankyo 3.2.1 Daiichi Sankyo Company Profile 3.2.2 Daiichi Sankyo Neuraminidase Inhibitors Drug Product Specification 3.2.3 Daiichi Sankyo Neuraminidase Inhibitors Drug Production Capacity, Revenue, Price and Gross Margin (2016-2021) 3.3 GSK 3.3.1 GSK Company Profile 3.3.2 GSK Neuraminidase Inhibitors Drug Product Specification 3.3.3 GSK Neuraminidase Inhibitors Drug Production Capacity, Revenue, Price and Gross Margin (2016-2021) 3.4 Gilead Sciences 3.4.1 Gilead Sciences Company Profile 3.4.2 Gilead Sciences Neuraminidase Inhibitors Drug Product Specification 3.4.3 Gilead Sciences Neuraminidase Inhibitors Drug Production Capacity, Revenue, Price and Gross Margin (2016-2021) 4 Global Neuraminidase Inhibitors Drug Market Competition by Market Players 4.1 Global Neuraminidase Inhibitors Drug Production Capacity Market Share by Market Players (2016-2021) 4.2 Global Neuraminidase Inhibitors Drug Revenue Market Share by Market Players (2016-2021) 4.3 Global Neuraminidase Inhibitors Drug Average Price by Market Players (2016-2021) 5 Global Neuraminidase Inhibitors Drug Production by Regions (2016-2021) 5.1 North America 5.1.1 North America Neuraminidase Inhibitors Drug Market Size (2016-2021) 5.1.2 Neuraminidase Inhibitors Drug Key Players in North America (2016-2021) 5.1.3 North America Neuraminidase Inhibitors Drug Market Size by Type (2016-2021) 5.1.4 North America Neuraminidase Inhibitors Drug Market Size by Application (2016-2021) 5.2 East Asia 5.2.1 East Asia Neuraminidase Inhibitors Drug Market Size (2016-2021) 5.2.2 Neuraminidase Inhibitors Drug Key Players in East Asia (2016-2021) 5.2.3 East Asia Neuraminidase Inhibitors Drug Market Size by Type (2016-2021) 5.2.4 East Asia Neuraminidase Inhibitors Drug Market Size by Application (2016-2021) 5.3 Europe 5.3.1 Europe Neuraminidase Inhibitors Drug Market Size (2016-2021) 5.3.2 Neuraminidase Inhibitors Drug Key Players in Europe (2016-2021) 5.3.3 Europe Neuraminidase Inhibitors Drug Market Size by Type (2016-2021) 5.3.4 Europe Neuraminidase Inhibitors Drug Market Size by Application (2016-2021) 5.4 South Asia 5.4.1 South Asia Neuraminidase Inhibitors Drug Market Size (2016-2021) 5.4.2 Neuraminidase Inhibitors Drug Key Players in South Asia (2016-2021) 5.4.3 South Asia Neuraminidase Inhibitors Drug Market Size by Type (2016-2021) 5.4.4 South Asia Neuraminidase Inhibitors Drug Market Size by Application (2016-2021) 5.5 Southeast Asia 5.5.1 Southeast Asia Neuraminidase Inhibitors Drug Market Size (2016-2021) 5.5.2 Neuraminidase Inhibitors Drug Key Players in Southeast Asia (2016-2021) 5.5.3 Southeast Asia Neuraminidase Inhibitors Drug Market Size by Type (2016-2021) 5.5.4 Southeast Asia Neuraminidase Inhibitors Drug Market Size by Application (2016-2021) 5.6 Middle East 5.6.1 Middle East Neuraminidase Inhibitors Drug Market Size (2016-2021) 5.6.2 Neuraminidase Inhibitors Drug Key Players in Middle East (2016-2021) 5.6.3 Middle East Neuraminidase Inhibitors Drug Market Size by Type (2016-2021) 5.6.4 Middle East Neuraminidase Inhibitors Drug Market Size by Application (2016-2021) 5.7 Africa 5.7.1 Africa Neuraminidase Inhibitors Drug Market Size (2016-2021) 5.7.2 Neuraminidase Inhibitors Drug Key Players in Africa (2016-2021) 5.7.3 Africa Neuraminidase Inhibitors Drug Market Size by Type (2016-2021) 5.7.4 Africa Neuraminidase Inhibitors Drug Market Size by Application (2016-2021) 5.8 Oceania 5.8.1 Oceania Neuraminidase Inhibitors Drug Market Size (2016-2021) 5.8.2 Neuraminidase Inhibitors Drug Key Players in Oceania (2016-2021) 5.8.3 Oceania Neuraminidase Inhibitors Drug Market Size by Type (2016-2021) 5.8.4 Oceania Neuraminidase Inhibitors Drug Market Size by Application (2016-2021) 5.9 South America 5.9.1 South America Neuraminidase Inhibitors Drug Market Size (2016-2021) 5.9.2 Neuraminidase Inhibitors Drug Key Players in South America (2016-2021) 5.9.3 South America Neuraminidase Inhibitors Drug Market Size by Type (2016-2021) 5.9.4 South America Neuraminidase Inhibitors Drug Market Size by Application (2016-2021) 5.10 Rest of the World 5.10.1 Rest of the World Neuraminidase Inhibitors Drug Market Size (2016-2021) 5.10.2 Neuraminidase Inhibitors Drug Key Players in Rest of the World (2016-2021) 5.10.3 Rest of the World Neuraminidase Inhibitors Drug Market Size by Type (2016-2021) 5.10.4 Rest of the World Neuraminidase Inhibitors Drug Market Size by Application (2016-2021) 6 Global Neuraminidase Inhibitors Drug Consumption by Region (2016-2021) 6.1 North America 6.1.1 North America Neuraminidase Inhibitors Drug Consumption by Countries 6.1.2 United States 6.1.3 Canada 6.1.4 Mexico 6.2 East Asia 6.2.1 East Asia Neuraminidase Inhibitors Drug Consumption by Countries 6.2.2 China 6.2.3 Japan 6.2.4 South Korea 6.3 Europe 6.3.1 Europe Neuraminidase Inhibitors Drug Consumption by Countries 6.3.2 Germany 6.3.3 United Kingdom 6.3.4 France 6.3.5 Italy 6.3.6 Russia 6.3.7 Spain 6.3.8 Netherlands 6.3.9 Switzerland 6.3.10 Poland 6.4 South Asia 6.4.1 South Asia Neuraminidase Inhibitors Drug Consumption by Countries 6.4.2 India 6.5 Southeast Asia 6.5.1 Southeast Asia Neuraminidase Inhibitors Drug Consumption by Countries 6.5.2 Indonesia 6.5.3 Thailand 6.5.4 Singapore 6.5.5 Malaysia 6.5.6 Philippines 6.6 Middle East 6.6.1 Middle East Neuraminidase Inhibitors Drug Consumption by Countries 6.6.2 Turkey 6.6.3 Saudi Arabia 6.6.4 Iran 6.6.5 United Arab Emirates 6.7 Africa 6.7.1 Africa Neuraminidase Inhibitors Drug Consumption by Countries 6.7.2 Nigeria 6.7.3 South Africa 6.8 Oceania 6.8.1 Oceania Neuraminidase Inhibitors Drug Consumption by Countries 6.8.2 Australia 6.9 South America 6.9.1 South America Neuraminidase Inhibitors Drug Consumption by Countries 6.9.2 Brazil 6.9.3 Argentina 6.10 Rest of the World 6.10.1 Rest of the World Neuraminidase Inhibitors Drug Consumption by Countries 7 Global Neuraminidase Inhibitors Drug Production Forecast by Regions (2022-2027) 7.1 Global Forecasted Production of Neuraminidase Inhibitors Drug (2022-2027) 7.2 Global Forecasted Revenue of Neuraminidase Inhibitors Drug (2022-2027) 7.3 Global Forecasted Price of Neuraminidase Inhibitors Drug (2022-2027) 7.4 Global Forecasted Production of Neuraminidase Inhibitors Drug by Region (2022-2027) 7.4.1 North America Neuraminidase Inhibitors Drug Production, Revenue Forecast (2022-2027) 7.4.2 East Asia Neuraminidase Inhibitors Drug Production, Revenue Forecast (2022-2027) 7.4.3 Europe Neuraminidase Inhibitors Drug Production, Revenue Forecast (2022-2027) 7.4.4 South Asia Neuraminidase Inhibitors Drug Production, Revenue Forecast (2022-2027) 7.4.5 Southeast Asia Neuraminidase Inhibitors Drug Production, Revenue Forecast (2022-2027) 7.4.6 Middle East Neuraminidase Inhibitors Drug Production, Revenue Forecast (2022-2027) 7.4.7 Africa Neuraminidase Inhibitors Drug Production, Revenue Forecast (2022-2027) 7.4.8 Oceania Neuraminidase Inhibitors Drug Production, Revenue Forecast (2022-2027) 7.4.9 South America Neuraminidase Inhibitors Drug Production, Revenue Forecast (2022-2027) 7.4.10 Rest of the World Neuraminidase Inhibitors Drug Production, Revenue Forecast (2022-2027) 7.5 Forecast by Type and by Application (2022-2027) 7.5.1 Global Sales Volume, Sales Revenue and Sales Price Forecast by Type (2022-2027) 7.5.2 Global Forecasted Consumption of Neuraminidase Inhibitors Drug by Application (2022-2027) 8 Global Neuraminidase Inhibitors Drug Consumption Forecast by Regions (2022-2027) 8.1 North America Forecasted Consumption of Neuraminidase Inhibitors Drug by Country 8.2 East Asia Market Forecasted Consumption of Neuraminidase Inhibitors Drug by Country 8.3 Europe Market Forecasted Consumption of Neuraminidase Inhibitors Drug by Countriy 8.4 South Asia Forecasted Consumption of Neuraminidase Inhibitors Drug by Country 8.5 Southeast Asia Forecasted Consumption of Neuraminidase Inhibitors Drug by Country 8.6 Middle East Forecasted Consumption of Neuraminidase Inhibitors Drug by Country 8.7 Africa Forecasted Consumption of Neuraminidase Inhibitors Drug by Country 8.8 Oceania Forecasted Consumption of Neuraminidase Inhibitors Drug by Country 8.9 South America Forecasted Consumption of Neuraminidase Inhibitors Drug by Country 8.10 Rest of the world Forecasted Consumption of Neuraminidase Inhibitors Drug by Country 9 Global Neuraminidase Inhibitors Drug Sales by Type (2016-2027) 9.1 Global Neuraminidase Inhibitors Drug Historic Market Size by Type (2016-2021) 9.2 Global Neuraminidase Inhibitors Drug Forecasted Market Size by Type (2022-2027) 10 Global Neuraminidase Inhibitors Drug Consumption by Application (2016-2027) 10.1 Global Neuraminidase Inhibitors Drug Historic Market Size by Application (2016-2021) 10.2 Global Neuraminidase Inhibitors Drug Forecasted Market Size by Application (2022-2027) 11 Global Neuraminidase Inhibitors Drug Manufacturing Cost Analysis 11.1 Neuraminidase Inhibitors Drug Key Raw Materials Analysis 11.1.1 Key Raw Materials 11.2 Proportion of Manufacturing Cost Structure 11.3 Manufacturing Process Analysis of Neuraminidase Inhibitors Drug 12 Global Neuraminidase Inhibitors Drug Marketing Channel, Distributors, Customers and Supply Chain 12.1 Marketing Channel 12.2 Neuraminidase Inhibitors Drug Distributors List 12.3 Neuraminidase Inhibitors Drug Customers 12.4 Neuraminidase Inhibitors Drug Supply Chain Analysis 13 Analyst's Viewpoints/Conclusions 14 Disclaimer
Related reports
Non-Hodgkin Lymphoma Therapeutics Market
$2000-$6000
Acrylic Teeth Market
$3600-$7000